ARTHEx Biotech CEO Frédéric Legros (L) and co-founder Beatriz Llamusí
May 3, 2023 07:00 AM EDT
Financing
Startups

ARTHEx nabs Se­ries B for clin­i­cal tri­al of ASO in my­oton­ic dy­s­tro­phy as Ver­tex’s deals heat up the space

Kyle LaHucik

Senior Reporter

ARTHEx Biotech has raised €42 mil­lion (about $46 mil­lion) in Se­ries B funds to bankroll an ear­ly-stage study of a drug can­di­date in my­oton­ic dy­s­tro­phy …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times